UBS Group Issues Pessimistic Forecast for ACADIA Pharmaceuticals (NASDAQ:ACAD) Stock Price

ACADIA Pharmaceuticals (NASDAQ:ACAD – Free Report) had its target price cut by UBS Group from $25.00 to $22.00 in a research note issued to investors on Monday morning,Benzinga reports. They currently have a buy rating on the biopharmaceutical company’s stock. Several other research analysts have also recently weighed in on the company. Needham & Company […]

Apr 29, 2025 - 07:35

ACADIA Pharmaceuticals (NASDAQ:ACAD – Free Report) had its target price cut by UBS Group from $25.00 to $22.00 in a research note issued to investors on Monday morning,Benzinga reports. They currently have a buy rating on the biopharmaceutical company’s stock. Several other research analysts have also recently weighed in on the company. Needham & Company […]